TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy

被引：0
|
作者：
Julia Eckardt
Christopher Schroeder
Peter Martus
Sorin Armeanu-Ebinger
Olga Kelemen
Axel Gschwind
Irina Bonzheim
Thomas Eigentler
Teresa Amaral
Stephan Ossowski
Olaf Rieß
Lukas Flatz
Claus Garbe
Andrea Forschner
机构：
[1] University Hospital of Tübingen,Department of Dermatology
[2] University Hospital Tübingen,Institute for Clinical Epidemiology and Applied Biometrics
[3] University Hospital Tübingen,Institute of Medical Genetics and Applied Genomics
[4] University Hospital Tübingen,Institute of Pathology and Neuropathology
[5] Charité Berlin,Department of Dermatology
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Anti-PD-1; Adjuvant; Melanoma; Checkpoint inhibition; Tumor mutational burden; RFS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：833 / 840
页数：7
相关论文
共 50 条
  • [1] TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
    Eckardt, Julia
    Schroeder, Christopher
    Martus, Peter
    Armeanu-Ebinger, Sorin
    Kelemen, Olga
    Gschwind, Axel
    Bonzheim, Irina
    Eigentler, Thomas
    Amaral, Teresa
    Ossowski, Stephan
    Riess, Olaf
    Flatz, Lukas
    Garbe, Claus
    Forschner, Andrea
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 833 - 840
  • [2] The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma
    Mooradian, Meghan J. J.
    Sullivan, Ryan J. J.
    CANCER, 2023, 129 (14) : 2117 - 2121
  • [3] TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.
    Forschner, Andrea
    Eckardt, Julia
    Martus, Peter
    Armeanu-Ebinger, Sorin
    Ossowski, Stephan
    Bonzheim, Irina
    Eigentler, Thomas
    Amaral, Teresa Maria Santos
    Flatz, Lukas
    Garbe, Claus
    Schroeder, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma
    Yunteng Wu
    Dongliang Wei
    Guoxin Ren
    Wei Guo
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2293 - 2300
  • [5] Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma
    Wu, Yunteng
    Wei, Dongliang
    Ren, Guoxin
    Guo, Wei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2293 - 2300
  • [6] Analysis of BRAF mutation status in high-risk malignant melanoma patients having received HD IFNa therapy in adjuvant setting
    Hlavata, Zuzana
    Salek, Tomas
    Andrezalova, Iveta
    Dolinsky, Jozef
    Svabova, Veronika
    Porsok, Stefan
    Berkovcova, Jitka
    Waczulikova, Iveta
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma
    Patrinely, J. Randall, Jr.
    Johnson, Rebecca
    Lawless, Aleigha R.
    Bhave, Prachi
    Sawyers, Amelia
    Dimitrova, Maya
    Yeoh, Hui Ling
    Palmeri, Marisa
    Ye, Fei
    Fan, Run
    Davis, Elizabeth J.
    Rapisuwon, Suthee
    Long, Georgina V.
    Haydon, Andrew
    Osman, Iman
    Mehnert, Janice M.
    Carlino, Matteo S.
    Sullivan, Ryan J.
    Menzies, Alexander M.
    Johnson, Douglas B.
    JAMA ONCOLOGY, 2021, 7 (05) : 744 - 748
  • [8] The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy
    Akman, Tulay
    Oztop, Ilhan
    Baskin, Yasemin
    Akbarpour, Mahdi
    Unal, Olcun Umit
    Oflazoglu, Utku
    Ellidokuz, Hulya
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 10
  • [9] The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy
    Tulay Akman
    Ilhan Oztop
    Yasemin Baskin
    Mahdi Akbarpour
    Olcun Umit Unal
    Utku Oflazoglu
    Hulya Ellidokuz
    Medical Oncology, 2015, 32
  • [10] A MULTICENTER CHARACTERIZATION OF CHRONIC TOXICITIES FOLLOWING ADJUVANT ANTI-PD-1 THERAPY FOR HIGH RISK RESECTED MELANOMA
    Patrinely, James
    Johnson, Rebecca
    Lawless, Aleigha
    Bhave, Prachi
    Sawyers, Amelia
    Dimitrova, Maya
    Yeohc, Hui
    Palmeri, Marisa
    Davis, Elizabeth
    Rapisuwon, Suthee
    Long, Georgina
    Haydon, Andrew
    Osman, Iman
    Mehnert, Janice
    Carlino, Matteo
    Sullivan, Ryan
    Menzies, Alexander
    Johnson, Douglas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A114 - A115
12345